New drug HuL001 enters first human safety trial for lung scarring disease
Disease control
Completed
This early-stage study tested a new drug called HuL001 in 24 people, including healthy volunteers and patients with idiopathic pulmonary fibrosis (IPF), a lung scarring disease. The main goal was to check safety and how the body handles the drug. This is a first step to see if Hu…
Phase: PHASE1 • Sponsor: HuniLife Biotechnology, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC